Obesity is an established risk factor for multiple cancers, but evidence has been limited on whether GLP-1 drugs -- popularly known as "skinny jabs" or weight-loss pens -- can reduce cancer risk among obese people without diabetes. Using propensity score matching and inverse probability of treatment weighting, the researchers compared more than 160,000 matched patients treated with GLP-1 drugs or lifestyle intervention alone over an average follow-up of about two years. Patients receiving GLP-1 medications had a 41 percent lower overall risk of developing the 13 obesity-related cancers identified by the U.S. National Cancer Institute, the study found. No significant reduction was found for breast cancer, while lung cancer was not included because it is not classified as an obesity-related cancer. NTUH Department of Obstetrics and Gynecology Director Chen Chi-hau (陳啓豪) said the findings suggest GLP-1 drugs have strong potential to help prevent endometrial cancer, for which obesity is a major risk factor.